NeoStem
420 Lexington Avenue
Suite 350
New York, New York 10170
Telephone: 1.212.584.4180

Intellectual Property

NeoStem is building a dominant IP portfolio within the field of cell therapy to protect its cutting edge technologies. Notably, this patent estate includes composition of matter patents for NBS10 (AMR-001) and the Company’s T Regulatory Cell product candidates. Our patent estate includes composition of matter and method claims and a geographic breadth of filings. NeoStem’s IP portfolio focuses on immunology, cardiology, orthopedic, wound healing, stem cell isolation and purification, and VSELTM treatment indications.

Targeted Cancer Immunotherapy Program

5 issued patents and 35 pending patents in the U.S. and OUS with coverage including:

  • Stem cell growth medium and methods of making and using same; Antigen-presenting cancer vaccines; Individualized high purity carcinoma initiating (stem) cells for target indications, methods and use of same; and rapid methods to produce high purity cancer initiating (stem) cells

Ischemic Repair Program

Broad and growing patent portfolio supports cardiac conditions and a broad range of other conditions caused by underlying ischemia. We have 17 granted composition of matter and method patents and 19 patent applications U.S. and O.U.S. pending. Specifically:

  • U.S. Patent No. 7,794,705 covering a chemotactic stem cell product enriched for CD34+ cells that treats injury from AMI;
  • U.S. Patent No. 8,088,370 covering the use of AMR-001 in the repair of injury caused by vascular insufficiency, including all forms of cardiac insufficiency, such as congestive heart failure, chronic myocardial ischemia and, we believe, vascular insufficiency induced ischemic conditions beyond the cardiac setting;
  • U.S. Patent Nos. 8,343,485 and 8,425,899 offering expanded breadth in AMR’s composition and treatment methods in the vascular insufficiency setting.
  • U.S. Continuation Application 13/295,240 and 13/685,585 expand range of cell concentration and serum components

Immune Modulation Program

  • Exclusive rights to 23 issued patents and 9 pending patents covering isolation, activation, expansion and methods of treating or preventing certain conditions and/or diseases using Tregs in U.S. and major international markets
  • Includes composition of matter patents and method patents

Tissue Regeneration Program

  • In-licensed from the University of Louisville the world-wide patent rights and know-how regarding the isolation, purification and therapeutic use of very small embryonic-like (VSEL™) stem cells

 

Information accurate as of November 2014.

NeoStem - Cell Therapy Development - Clinical